Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Corey

Showing results (411-420 of 551) with videos related to

Pageof 56
Sort By:
Journal of Global Health|June 23, 2023
Post-COVID symptom profiles and duration in a global convalescent COVID-19 observational cohort: Correlations with demographics, medical history, acute COVID-19 severity and global regionShelly Karuna, Jorge A Gallardo-Cartagena, Deborah Theodore, et al.
The Lancet. Infectious Diseases|May 17, 2011
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b studyGlenda E Gray, Mary Allen, Zoe Moodie, et al.
JCI Insight|August 12, 2024
Expansion of the HSV-2-specific T cell repertoire in skin after immunotherapeutic HSV-2 vaccineEmily S Ford, Alvason Z Li, Kerry J Laing, et al.
Vaccine|January 11, 2011
A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjectsMichael C Keefer, Sharon E Frey, Marnie Elizaga, et al.
The Lancet. HIV|October 12, 2019
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trialGiuseppe Pantaleo, Holly Janes, Shelly Karuna, et al.
Frontiers in Immunology|September 23, 2021
Tissue-Resident-Memory CD8<sup>+</sup> T Cells Bridge Innate Immune Responses in Neighboring Epithelial Cells to Control Human Genital HerpesTao Peng, Khamsone Phasouk, Catherine N Sodroski, et al.
Ebiomedicine|January 25, 2021
Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trialsYunda Huang, Logashvari Naidoo, Lily Zhang, et al.
Clinical and Vaccine Immunology : CVI|April 22, 2016
Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year GapGlenda E Gray, Kenneth H Mayer, Marnie L Elizaga, et al.
Science Translational Medicine|November 22, 2019
Antigenic competition in CD4<sup>+</sup> T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trialEsper G Kallas, Nicole A Grunenberg, Chenchen Yu, et al.
Plos One|September 2, 2016
Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African ParticipantsGavin Churchyard, Koleka Mlisana, Shelly Karuna, et al.
Pageof 56

Showing results (411-420 of 551) with videos related to

Sort By:
Pageof 56
Journal of Global Health|June 23, 2023
Post-COVID symptom profiles and duration in a global convalescent COVID-19 observational cohort: Correlations with demographics, medical history, acute COVID-19 severity and global regionShelly Karuna, Jorge A Gallardo-Cartagena, Deborah Theodore, et al.
The Lancet. Infectious Diseases|May 17, 2011
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b studyGlenda E Gray, Mary Allen, Zoe Moodie, et al.
JCI Insight|August 12, 2024
Expansion of the HSV-2-specific T cell repertoire in skin after immunotherapeutic HSV-2 vaccineEmily S Ford, Alvason Z Li, Kerry J Laing, et al.
Vaccine|January 11, 2011
A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjectsMichael C Keefer, Sharon E Frey, Marnie Elizaga, et al.
The Lancet. HIV|October 12, 2019
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trialGiuseppe Pantaleo, Holly Janes, Shelly Karuna, et al.
Frontiers in Immunology|September 23, 2021
Tissue-Resident-Memory CD8<sup>+</sup> T Cells Bridge Innate Immune Responses in Neighboring Epithelial Cells to Control Human Genital HerpesTao Peng, Khamsone Phasouk, Catherine N Sodroski, et al.
Ebiomedicine|January 25, 2021
Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trialsYunda Huang, Logashvari Naidoo, Lily Zhang, et al.
Clinical and Vaccine Immunology : CVI|April 22, 2016
Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year GapGlenda E Gray, Kenneth H Mayer, Marnie L Elizaga, et al.
Science Translational Medicine|November 22, 2019
Antigenic competition in CD4<sup>+</sup> T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trialEsper G Kallas, Nicole A Grunenberg, Chenchen Yu, et al.
Plos One|September 2, 2016
Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African ParticipantsGavin Churchyard, Koleka Mlisana, Shelly Karuna, et al.
Pageof 56